<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Database (Oxford)</journal-id>
    <journal-id journal-id-type="iso-abbrev">Database (Oxford)</journal-id>
    <journal-id journal-id-type="publisher-id">databa</journal-id>
    <journal-title-group>
      <journal-title>Database: The Journal of Biological Databases and Curation</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1758-0463</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">5502365</article-id>
    <article-id pub-id-type="doi">10.1093/database/bax005</article-id>
    <article-id pub-id-type="publisher-id">bax005</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Database Tool</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>The HIV oligonucleotide database (HIVoligoDB)</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Carneiro</surname>
          <given-names>João</given-names>
        </name>
        <xref ref-type="aff" rid="bax005-aff1">a</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Resende</surname>
          <given-names>Adriana</given-names>
        </name>
        <xref ref-type="aff" rid="bax005-aff1">a</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Pereira</surname>
          <given-names>Filipe</given-names>
        </name>
        <xref ref-type="corresp" rid="bax005-cor1"/>
        <!--<email>fpereirapt@gmail.com</email>-->
      </contrib>
    </contrib-group>
    <aff id="bax005-aff1"><label>a</label>Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), University of Porto, Terminal de Cruzeiros do Porto de LeixAv. General Norton de Matos s/n 4450-208 Porto</aff>
    <author-notes>
      <corresp id="bax005-cor1"><label>*</label>Corresponding author: Tel: (+351) 22 340 18 00; Fax (+351) 22 339 06 08; Email: <email>fpereirapt@gmail.com</email></corresp>
      <fn id="bax005-FM1">
        <p>Citation details: Carneiro,J, Resende,A., and Pereira,F. The HIV oligonucleotide database (HIVoligoDB). <italic>Database</italic> (2017) Vol. 2017: article ID bax005; doi:10.1093/database/bax005</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2017-03-18">
      <day>18</day>
      <month>3</month>
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>18</day>
      <month>3</month>
      <year>2017</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>2017</volume>
    <elocation-id>bax005</elocation-id>
    <history>
      <date date-type="received">
        <day>03</day>
        <month>9</month>
        <year>2016</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>1</month>
        <year>2017</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>1</month>
        <year>2017</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2017. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/" license-type="cc-by">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="bax005.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>The human immunodeficiency virus (HIV) is associated with one of the most widespread infectious disease, the acquired immunodeficiency syndrome (AIDS). The development of antiretroviral drugs and methods for virus detection requires a comprehensive analysis of the HIV genomic diversity, particularly in the binding sites of oligonucleotides. Here, we describe a versatile online database (HIVoligoDB) with oligonucleotides selected for the diagnosis of HIV and treatment of AIDS. Currently, the database provides an interface for visualization, analysis and download of 380 HIV-1 and 65 HIV-2 oligonucleotides annotated according to curated reference genomes. The database also allows the selection of the most conserved HIV genomic regions for the development of molecular diagnostic assays and sequence-based candidate therapeutics.</p>
      <p>
        <bold>Database URL:</bold>
        <ext-link ext-link-type="uri" xlink:href="http://portugene.com/HIVoligoDB">http://portugene.com/HIVoligoDB</ext-link>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <named-content content-type="funder-name">CIIMAR—FCT and ERDF</named-content>
        </funding-source>
        <award-id>UID/Multi/04423/2013</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="5"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro">
    <title>Introduction</title>
    <p>The human immunodeficiency virus (HIV) is a significant threat to public health, being associated with the acquired immunodeficiency syndrome (AIDS), one of the most widespread infectious diseases at global scale (<xref rid="bax005-B1" ref-type="bibr">1</xref>). Two HIV types have been identified. HIV-1 is responsible for most cases of AIDS while HIV-2 is confined mainly to West Africa, although several HIV-2 infections can be found in Mozambique, Angola, France and Portugal (<xref rid="bax005-B2" ref-type="bibr">2</xref>). HIV-2 infection are less virulent and transmissible than HIV-1, although HIV-2 is known to also cause AIDS (<xref rid="bax005-B3" ref-type="bibr">3</xref>). The HIV genome contains three major genes encoding essential enzymes and structural proteins: <italic>gag</italic>, <italic>pol</italic> and <italic>env</italic>. The single-stranded RNA genome is converted by the reverse transcriptase into a double-stranded DNA that is integrated into the genome of infected individuals (<xref rid="bax005-B4" ref-type="bibr">4</xref>). The process of genome replication is a source of genetic variability due to the absence of proofreading ability of the reverse transcriptase, resulting in a high mutation rate (<xref rid="bax005-B5" ref-type="bibr">5</xref>, <xref rid="bax005-B6" ref-type="bibr">6</xref>).</p>
    <p>A considerable number of nucleic acid techniques (NATs) have been developed for clinical diagnosis, genetic characterization of isolates, identification of genotypes, determination of viral loads, detection of drug resistance mutations and epidemiological studies (<xref rid="bax005-B7" ref-type="bibr">7</xref>, <xref rid="bax005-B8" ref-type="bibr">8</xref>). In recent years, synthetic oligonucleotides complementary to HIV-1 RNA have been tested as possible antiviral or virucidal agents. Oligonucleotide-based therapeutics include antisense RNA, ribozymes, decoy RNAs, aptamers and small interfering RNA (<xref rid="bax005-B9" ref-type="bibr">9</xref>). Despite the abundance of DNA or RNA molecules targeting HIV, no organized repository of sequences is available. Some databases include genomic information for HIV-1 and HIV-2 (see online <xref ref-type="supplementary-material" rid="sup1">supplementary material</xref> for Figure S1). For example, the NCBI Probe Database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/probe">https://www.ncbi.nlm.nih.gov/probe</ext-link>) includes oligonucleotides for HIV, but lack any data on sequence conservation. The Los Alamos National Laboratory (<ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/content/index">http://www.hiv.lanl.gov/content/index</ext-link>) and the Stanford University (<ext-link ext-link-type="uri" xlink:href="http://hivdb.stanford.edu/">http://hivdb.stanford.edu/</ext-link>) HIV databases include information on genomic sequences and drug resistance mutations, but no information on oligonucleotides (<xref rid="bax005-B10" ref-type="bibr">10</xref>).</p>
    <p>Here, we present the HIV oligonucleotide database (HIVoligoDB) describing a set of oligonucleotides and genomic regions that can be used to improve the efficiency of HIV epidemiological studies and nucleic acid-based assays (<xref ref-type="fig" rid="bax005-F1">Figure 1</xref>).</p>
    <fig id="bax005-F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Screenshot of the data and tools included in the HIVoligoID. </p>
      </caption>
      <graphic xlink:href="bax005f1"/>
    </fig>
  </sec>
  <sec>
    <title>Materials and Methods</title>
    <p>The HIVoligoDB (<ext-link ext-link-type="uri" xlink:href="http://portugene.com/HIVoligoDB">http://portugene.com/HIVoligoDB</ext-link>) includes 380 HIV-1 (236 primers and 144 probes) and 65 HIV-2 oligonucleotides (57 primers and 8 probes) retrieved from 54 peer-reviewed publications and the NCBI Probe Database. Each oligonucleotide has a specific database code (for example, HIV1ID0001) and is associated with a reference genome (K03455.1 for HIV-1 and M15390 for HIV-2). The database provides descriptive webpages (e.g. type of target, related publications) for each oligonucleotide and a search engine to access dynamic tables with numeric data and multiple sequence alignments with complete HIV genomes. The multiple sequence alignments were retrieved from the Los Alamos National Laboratory (<ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/content/index">http://www.hiv.lanl.gov/content/index</ext-link>). The HIV-1 alignment includes sequences from all HIV-1 described sub-types (including non-M groups) (<xref rid="bax005-B11" ref-type="bibr">11</xref>). The HIV-2 alignment includes a carefully chosen subset of HIV-2 and SIV/SMM (simian immunodeficiency virus) sequences from the HIV Sequence Compendium (<xref rid="bax005-B12" ref-type="bibr">12</xref>).</p>
    <p>The database ranks all oligonucleotides considering three main measures of sequence conservation: <bold>(</bold>a) percentage of identical sites (PIS), calculated by dividing the number of equal positions in the alignment for an oligonucleotide by its length; (b) percentage of identical sites in the last five nucleotides at the 3′ end of the oligonucleotide (3′PIS)—the most critical regions for an efficient binding to the template DNA during PCR and (c) percentage of pairwise identity (PPI), calculated by counting the average number of pairwise matches across the positions of the alignment, divided by the total number of pairwise comparisons. The ranking score (‘HIV score’) considers the mean value of the three different measures (PIS, 3′PIS and PPI). In theory, high PIS and PPI values indicates that an oligonucleotide binds to a conserved genomic region, increasing the probability of successful binding in a PCR or other technique. Calculations of melting temperature (<italic>T</italic><sub>m</sub>) of each PCR primer were determined using the BioPython Melting Temperature module with Santa Lucia parameters (<xref rid="bax005-B13" ref-type="bibr">13</xref>) and the dimer free energy with the method used in Vienna Package (<xref rid="bax005-B14" ref-type="bibr">14</xref>). The melting temperatures and self-dimmer free energies are described in the table <bold>‘</bold>Oligonucleotides properties’ that are available through the menu <bold>‘</bold>Search’.</p>
    <p>The database works with major web browsers (e.g. Internet Explorer, Mozilla Firefox, Chrome). The SQLite local database is used for data storage and runs on an Apache web server. The dynamic HTML pages were implemented using CGI-Perl and JavaScript and the dataset tables using the JQuery plugin DataTables v1.9.4 (<ext-link ext-link-type="uri" xlink:href="http://datatables.net/">http://datatables.net/</ext-link>). The database uses java graphics and dynamic tables. Python and perl algorithms implemented with BioPerl were used to perform identity and pairwise calculations.</p>
  </sec>
  <sec sec-type="results">
    <title>Results</title>
    <p>The HIVoligoDB is a free resource with detailed records of oligonucleotides to study HIV-1 and HIV-2. The database has a core integration of multiple data from different sources, which facilitates the analysis of hundreds of records through search and filtering processes. The HIVoligoDB is being constantly updated with new oligonucleotides added once they are described in peer-reviewed publications. We have used the HIVoligoDB to perform calculations over 445 oligonucleotides located in different HIV-1 and HIV-2 genomic regions (see online <xref ref-type="supplementary-material" rid="sup1">supplementary material</xref> for Figure S2). The multiple sequence alignment of HIV-1 (alig01) has a PIS of 15.26% and a PPI of 85.46%. The HIV-2 alignment (alig02) has a PIS of 29.09% and a PPI of 83.20%. The researcher can use the database to access the most conserved oligonucleotides (<xref ref-type="table" rid="bax005-T1">Table 1</xref>). Our analyses revealed that oligonucleotides HIV1ID0037 (HIV score of 81.79%), HIV1ID0146 (79.43%) and HIV1ID0179 (78.91%) are the most conserved for HIV-1. The HIV-1 PCR primer pair with the highest HIV score (80.35%) was HIV1ID0037–HIV1ID0179. The most conserved oligonucleotides for HIV-2 were HIV2ID0015 (95.14%), HIV2ID0061 (87.49%) and HIV2ID0057 (84.71%). The PCR primer pair with the highest HIV score (91.31%) for HIV-2 was HIV2ID0015–HIV2ID0061. Similar melting temperatures (<italic>T</italic><sub>m</sub>) in oligonucleotide pairs are important for the efficiency of PCR (<xref rid="bax005-B15" ref-type="bibr">15</xref>). We identified some PCR primer pairs with similar <italic>T</italic><sub>m</sub> and high HIV scores. For example, the primers HIV1ID0037 (<italic>T</italic><sub>m</sub> of 55.97 °C) and HIV1ID0179 (<italic>T</italic><sub>m</sub> of 58.72 °C) have similar <italic>T</italic><sub>m</sub> values and a high HIV score (80.35).
<table-wrap id="bax005-T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Oligonucleotides with highest HIV score for HIV-1 and HIV-2</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Virus</th><th rowspan="1" colspan="1">Code</th><th rowspan="1" colspan="1">Type</th><th rowspan="1" colspan="1">Original name</th><th rowspan="1" colspan="1">Target length</th><th rowspan="1" colspan="1">Sequence (5′–3′)</th><th rowspan="1" colspan="1">Position in reference genome</th><th rowspan="1" colspan="1">Genomic region</th><th rowspan="1" colspan="1">HIV Score</th></tr></thead><tbody><tr><td rowspan="10" colspan="1">HIV-1</td><td rowspan="1" colspan="1">HIV1ID0037</td><td rowspan="1" colspan="1">PCR primer reverse</td><td rowspan="1" colspan="1">NP174</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">CTACYGCCCCTTYACCTTTCC</td><td rowspan="1" colspan="1">4957-4977</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1">81.79</td></tr><tr><td rowspan="1" colspan="1">HIV1ID0146</td><td rowspan="1" colspan="1">Degenerate PCR primer</td><td rowspan="1" colspan="1">env27F</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">CTGGYATAGTGCARCARCA</td><td rowspan="1" colspan="1">7861-7879</td><td rowspan="1" colspan="1"><italic>env</italic></td><td rowspan="1" colspan="1">79.43</td></tr><tr><td rowspan="1" colspan="1">HIV1ID0179</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">HPOL4235</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">CCCTACAATCCCCAAAGTCAAGG</td><td rowspan="1" colspan="1">4653-4675</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1">78.91</td></tr><tr><td rowspan="1" colspan="1">HIV1ID0163</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">intF</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">CCCTACAATCCCCAAAGTCA</td><td rowspan="1" colspan="1">4653-4672</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1">78.87</td></tr><tr><td rowspan="1" colspan="1">HIV1ID0116</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">E180</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">GTCTGGTATAGTGCAACAGCA</td><td rowspan="1" colspan="1">7860-7879</td><td rowspan="1" colspan="1"><italic>env</italic></td><td rowspan="1" colspan="1">78.38</td></tr><tr><td rowspan="1" colspan="1">HIV1ID0182</td><td rowspan="1" colspan="1">PCR primer reverse</td><td rowspan="1" colspan="1">HPOL4481</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">GCTGTCCCTGTAATAAACCCG</td><td rowspan="1" colspan="1">4899-4919</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1">77.9</td></tr><tr><td rowspan="1" colspan="1">HIV1ID0283</td><td rowspan="1" colspan="1">siRNA antisense</td><td rowspan="1" colspan="1">si4652</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">UGACUUUGGGGAUUGUAGGGA</td><td rowspan="1" colspan="1">4652-4672</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">HIV1ID0017</td><td rowspan="1" colspan="1">Probe</td><td rowspan="1" colspan="1">H-1 probe</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">AATGAGGAGGCTGCAGAATGGGA</td><td rowspan="1" colspan="1">1405-1427</td><td rowspan="1" colspan="1"><italic>gag</italic></td><td rowspan="1" colspan="1">77.24</td></tr><tr><td rowspan="1" colspan="1">HIV1ID0087</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">G80</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">ATGAGAGAACCAAGGGGAAGTGA</td><td rowspan="1" colspan="1">1471-1493</td><td rowspan="1" colspan="1"><italic>gag</italic></td><td rowspan="1" colspan="1">76.61</td></tr><tr><td rowspan="1" colspan="1">HIV1ID0052</td><td rowspan="1" colspan="1">PCR primer reverse</td><td rowspan="1" colspan="1">gag R4</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">TTGATGGTCTCTTTTAACATTTGCATGGCTGC</td><td rowspan="1" colspan="1">1375-1406</td><td rowspan="1" colspan="1"><italic>gag</italic></td><td rowspan="1" colspan="1">76.18</td></tr><tr><td rowspan="1" colspan="1">HIV-2</td><td rowspan="1" colspan="1">HIV2ID0015</td><td rowspan="1" colspan="1">PCR primer reverse</td><td rowspan="1" colspan="1">A-Loop B</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">AATTTTAAAAGAAGGGGAGGA</td><td rowspan="1" colspan="1">4607-4627</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1">95.14</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0061</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">POL OG 479 INV</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">GGAGCAGTCCTAGTCAAGGTAGG</td><td rowspan="1" colspan="1">4796-4818</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1">87.49</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0057</td><td rowspan="1" colspan="1">PCR primer reverse</td><td rowspan="1" colspan="1">PFD INV</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">CTGCCTTCTCTGAAATAGACC</td><td rowspan="1" colspan="1">4729-4749</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1">84.71</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0044</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">EB7</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">CCYAGGCAAGCATGGTG</td><td rowspan="1" colspan="1">7149-7165</td><td rowspan="1" colspan="1"><italic>env</italic></td><td rowspan="1" colspan="1">83.47</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0017</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">Seq.ID.NO.19</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">CCTCAATTCTCTCTTTGGAAAAGACC</td><td rowspan="1" colspan="1">2084-2109</td><td rowspan="1" colspan="1"><italic>gag</italic></td><td rowspan="1" colspan="1">82.91</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0041</td><td rowspan="1" colspan="1">PCR primer reverse</td><td rowspan="1" colspan="1">EB6</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">CCATTRAAGCCAAACCAWGT</td><td rowspan="1" colspan="1">6945-6964</td><td rowspan="1" colspan="1"><italic>env</italic></td><td rowspan="1" colspan="1">81.32</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0060</td><td rowspan="1" colspan="1">PCR primer reverse</td><td rowspan="1" colspan="1">POL OG 479</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">CCTACCTTGACTAGGACTGCTCC</td><td rowspan="1" colspan="1">4796-4818</td><td rowspan="1" colspan="1"><italic>pol</italic></td><td rowspan="1" colspan="1">80.82</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0043</td><td rowspan="1" colspan="1">PCR primer reverse</td><td rowspan="1" colspan="1">EB5</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">CTCCTCTGCAGTTAGTCCAC</td><td rowspan="1" colspan="1">7310-7329</td><td rowspan="1" colspan="1"><italic>env</italic></td><td rowspan="1" colspan="1">80.61</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0003</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">SR64, envF</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">CTCCAGGCAAGAGTCACTGCTAT</td><td rowspan="1" colspan="1">7869-7891</td><td rowspan="1" colspan="1"><italic>env</italic></td><td rowspan="1" colspan="1">80.44</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HIV2ID0055</td><td rowspan="1" colspan="1">PCR primer forward</td><td rowspan="1" colspan="1">X410</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">CACCTCAATTCTCTCTTTGGA</td><td rowspan="1" colspan="1">2082-2102</td><td rowspan="1" colspan="1"><italic>gag</italic></td><td rowspan="1" colspan="1">80.09</td></tr></tbody></table></table-wrap></p>
    <p>Extensive genetic diversity has been observed in HIV (<xref rid="bax005-B16" ref-type="bibr">16</xref>), and several works have used a multiplicity of techniques to study these viruses (<xref rid="bax005-B16" ref-type="bibr">16–23</xref>). The HIV score allows users to select the most accurate oligonucleotides for different techniques. The oligonucleotides can also be associated with the technique where they were used by the first time. Moreover, each oligonucleotide can be easily associated with the respective region in the reference genome.</p>
    <p>The most conserved regions for HIV-1 were the <italic>gag</italic> and <italic>pol</italic>, while LTRs had the lowest HIV scores (see online <xref ref-type="supplementary-material" rid="sup1">supplementary material</xref> for Figure S3). The protease and p51 RT regions (located inside <italic>pol</italic> region) include 11% (43 oligonucleotides) of all oligonucleotides. The PCR primers’ pairs for HIV-1 with the highest HIV score in these genomic regions were HIV1ID0073–HIV1ID0206 (score of 73.61 and <italic>T</italic><sub>m</sub> of 58.9 °C and 60.9 °C) and HIV1ID0035–HIV1ID087 (a score of 73.28, <italic>T</italic><sub>m</sub> of 53.9 °C and 57.1 °C). For HIV-2, the oligonucleotides with highest conservation scores were those located in the <italic>pol</italic> region, and the lowest located in the <italic>tat</italic> region (see online <xref ref-type="supplementary-material" rid="sup1">supplementary material</xref> for Figure 3B). The <italic>pol</italic> region included 21.5% of all oligonucleotides. The primers pairs for HIV-2 with the highest HIV score located in the <italic>pol</italic> region were HIV2ID0015HIV2ID0061 (a score of 91.31, <italic>T</italic><sub>m</sub> of 49.40°C and 58.80°C) and HIV2ID0057- HIV2ID0061 (a score of 86.1, <italic>T</italic><sub>m</sub> of 51.65°C and 58.80°C). By combining different set of PCR primers, a complete amplification of the protease and p51 RT regions can be performed for detection of drug resistant mutations.</p>
    <p>We calculated the PIS and PPI values for all 30 nt sliding windows across the HIV-1 and HIV-2 alignments, which allow the identification of the most conserved genomic regions in these viruses (see online <xref ref-type="supplementary-material" rid="sup1">supplementary material</xref> for Figures S4 and S5). This information can be used to design new oligonucleotides.</p>
  </sec>
  <sec>
    <title>Examples of Use</title>
    <p>In order to select the oligonucleotides located in the most conserved HIV-1 genomic regions, the user can go to the ‘Search’ tab on the top menu bar, and open the ‘The best oligonucleotides’ tab. The table is automatically ordered by the ‘HIV Score’ column filter. The user can now access the oligonucleotide information by clicking in the oligonucleotide ID hyperlink, which shows the summary information for that record. The database can also be used to filter all columns using the search tool. For instance, to access the best oligonucleotide for HIV-1 located in <italic>pol</italic> region, the user can type ‘pol’ in the search box. The database table now shows only the records where the word pol is found. The oligonucleotide with highest ‘HIV score’ in the <italic>pol</italic> region is HIV1ID0037.</p>
    <p>If the aim is to design a new oligonucleotide, the user can click on the ‘Genome variation’ tab on the top menu bar. The user can then select the alignment to display in the graph (HIV-1 or HIV-2), which describe a sliding window analysis of 30 nt windows with 1 nt of overlap of PIS and PPI values. The list of the most conserved genomic regions can be found in a table. For example, the genomic region 5524–5554 of the HIV-1 alignment has the highest PIS value (64.52%). This section of the alignment can be visualized by clicking on the 5524–5554 value in the table. The user can also visualize any window of the alignment by using the ‘Show window in alignment’ box.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>Portuguese Foundation for Science and Technology (FCT), European Regional Development Fund (ERDF) [IF/01356/2012 to F.P. and SFRH/BPD/100912/2014 to J.C.] and Direção-Geral da Saúde and Coordenação Nacional para a Infeção VIH/SIDA [VIH/SAU/0011/2011]. CIIMAR—FCT and ERDF [UID/Multi/04423/2013].</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary data</title>
    <p><xref ref-type="supplementary-material" rid="sup1">Supplementary data</xref> are available at <italic>Database</italic> Online.</p>
    <p><bold><italic>Conflict of interest</italic></bold>: None declared.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sup1">
      <label>Supplementary Data</label>
      <media xlink:href="bax005_Supp.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ref-list>
    <title>References</title>
    <ref id="bax005-B1">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group> (<year>2001</year>) <article-title>Infectious diseases: considerations for the 21st century</article-title>. <source>Clin. Infect. Dis</source>, <volume>32</volume>, <fpage>675</fpage>–<lpage>685</lpage>.<pub-id pub-id-type="pmid">11229834</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeCock</surname><given-names>K.M.</given-names></name></person-group><etal/> (<year>1993</year>) <article-title>Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic</article-title>. <source>JAMA</source>, <volume>270</volume>, <fpage>2083</fpage>–<lpage>2086</lpage>.<pub-id pub-id-type="pmid">8147962</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B3">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marlink</surname><given-names>R.</given-names></name></person-group><etal/> (<year>1994</year>) <article-title>Reduced rate of disease development after HIV-2 infection as compared to HIV-1</article-title>. <source>Science</source>, <volume>265</volume>, <fpage>1587</fpage>–<lpage>1590</lpage>.<pub-id pub-id-type="pmid">7915856</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B4">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Briant</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>) <article-title>HIV-1 assembly, release and maturation</article-title>. <source>World J. AIDS</source>, <volume>1</volume>, <fpage>111</fpage>–<lpage>130</lpage>.</mixed-citation>
    </ref>
    <ref id="bax005-B5">
      <label>5</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cann</surname><given-names>A.J.</given-names></name></person-group> (<year>2005</year>) <source>Principles of molecular virology</source><edition>4th Edition</edition>, <comment>Academic Press, United States, pp. 1–352</comment>.</mixed-citation>
    </ref>
    <ref id="bax005-B6">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smyth</surname><given-names>R.P.</given-names></name>, <name name-style="western"><surname>Davenport</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Mak</surname><given-names>J</given-names></name></person-group> (<year>2012</year>) <article-title>The origin of genetic diversity in HIV-1</article-title>. <source>Virus Res.</source>, <volume>169</volume>, <fpage>415</fpage>–<lpage>429</lpage>.<pub-id pub-id-type="pmid">22728444</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y.W.</given-names></name>, <name name-style="western"><surname>Procop</surname><given-names>G.W.</given-names></name>, <name name-style="western"><surname>Persing</surname><given-names>D.H.</given-names></name></person-group> (<year>1997</year>) <article-title>Molecular diagnostics of infectious diseases</article-title>. <source>Clin. Chem</source>., <volume>43</volume>, <fpage>2021</fpage>–<lpage>2038</lpage>.<pub-id pub-id-type="pmid">9365385</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barry</surname><given-names>E.</given-names></name></person-group> (<year>1990</year>) <article-title>New molecular techniques for microbial epidemiology and the diagnosis of infectious diseases</article-title>. <source>J. Infect. Dis.</source>, <volume>161</volume>, <fpage>595</fpage>–<lpage>602</lpage>.<pub-id pub-id-type="pmid">2108224</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>J.J.</given-names></name></person-group><etal/> (<year>2006</year>) <article-title>Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: Chemistry and cell delivery</article-title>. <source>Biochim. Biophys. Acta: Biomembr</source>., <volume>1758</volume>, <fpage>290</fpage>–<lpage>300</lpage>.</mixed-citation>
    </ref>
    <ref id="bax005-B10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuiken</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Korber</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Shafer</surname><given-names>R.W.</given-names></name></person-group> (<year>2003</year>) <article-title>HIV sequence databases</article-title>. <source>AIDS Rev</source>., <volume>5</volume>, <fpage>52</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">12875108</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leitner</surname><given-names>T.</given-names></name></person-group><etal/> (<year>2005</year>) <article-title>HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005</article-title>. <source>HIV Seq. Compend</source>., <volume>3</volume>, <fpage>41</fpage>–<lpage>48</lpage>.</mixed-citation>
    </ref>
    <ref id="bax005-B12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abecasis</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Vandamme</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lemey</surname><given-names>P.</given-names></name></person-group> (<year>2006</year>) <article-title>Sequence alignment in HIV Computational analysis</article-title>. <source>Reviews</source>, <fpage>2</fpage>–<lpage>16</lpage>.</mixed-citation>
    </ref>
    <ref id="bax005-B13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>SantaLucia</surname><given-names>Jr. J.</given-names></name>, <name name-style="western"><surname>Hicks</surname><given-names>D.</given-names></name></person-group> (<year>2004</year>) <article-title>The thermodynamics of DNA structural motifs. </article-title>. <source>Annu Rev Biophys Biomol Struct</source>., <volume>33</volume>, <fpage>415</fpage>–<lpage>440</lpage>.<pub-id pub-id-type="pmid">15139820</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tafer</surname><given-names>H.</given-names></name></person-group><etal/> (<year>2011</year>) <article-title>ViennaRNA Package 2.0</article-title>. <source>Algorithms Mol. Biol</source>., <volume>6</volume>, <fpage>26.</fpage><pub-id pub-id-type="pmid">22115189</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenz</surname><given-names>T.C.</given-names></name></person-group> (<year>2012</year>) <article-title>Polymerase chain reaction: basic protocol plus troubleshooting and optimization strategies</article-title>. <source>J. Vis. Exp</source>., <fpage>e3998.</fpage><pub-id pub-id-type="pmid">22664923</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smyth</surname><given-names>R.P.</given-names></name>, <name name-style="western"><surname>Negroni</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>) <article-title>A step forward understanding HIV-1 diversity</article-title>. <source>Retrovirology</source>, <volume>13</volume>, <fpage>27.</fpage><pub-id pub-id-type="pmid">27093884</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B17">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khodakov</surname><given-names>D.A.</given-names></name></person-group><etal/> (<year>2008</year>) <article-title>An oligonucleotide microarray for multiplex real-time PCR identification of HIV-1, HBV, and HCV</article-title>. <source>Biotechniques</source>, <volume>44</volume>, <fpage>241</fpage>–<lpage>248</lpage>.<pub-id pub-id-type="pmid">18330353</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udaykumar</surname><given-names/></name></person-group><etal/> (<year>1994</year>) <article-title>Enhanced diagnostic efficiency of the polymerase chain reaction by co-amplification of multiple regions of HIV-1 and HIV-2</article-title>. <source>J. Virol. Methods</source>, <volume>49</volume>, <fpage>37</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">7829590</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohrman</surname><given-names>B. A.</given-names></name>, <name name-style="western"><surname>Richards-Kortum</surname><given-names>R.R.</given-names></name></person-group> (<year>2012</year>) <article-title>A paper and plastic device for performing recombinase polymerase amplification of HIV DNA</article-title>. <source>Lab Chip</source>, <volume>12</volume>, <fpage>3082.</fpage><pub-id pub-id-type="pmid">22733333</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>D.S.</given-names></name></person-group><etal/> (<year>2013</year>) <article-title>Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification</article-title>. <source>MBio</source>, <volume>4</volume>, pii: <fpage>e00135</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">23549916</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.H.</given-names></name></person-group><etal/> (<year>2013</year>) <article-title>An integrated chip capable of performing sample pretreatment and nucleic acid amplification for HIV-1 detection</article-title>. <source>Biosens. Bioelectron</source>., <volume>41</volume>, <fpage>484</fpage>–<lpage>491</lpage>.<pub-id pub-id-type="pmid">23083906</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>K.A.</given-names></name></person-group><etal/> (<year>2012</year>) <article-title>Isothermal amplification using a chemical heating device for point-of-care detection of HIV-1</article-title>. <source>PLoS One</source>, <volume>7</volume>, <fpage>e31432</fpage><pub-id pub-id-type="pmid">22384022</pub-id></mixed-citation>
    </ref>
    <ref id="bax005-B23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>K.A.</given-names></name></person-group><etal/> (<year>2014</year>) <article-title>Real-time detection of HIV-2 by reverse transcription-loop-mediated isothermal amplification</article-title>. <source>J. Clin. Microbiol</source>, <volume>52</volume>, <fpage>2674</fpage>–<lpage>2676</lpage>.<pub-id pub-id-type="pmid">24789187</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
